The therapeutic dilemma of immunosuppressive drugs for refractory cardiac sarcoidosis in COVID‐19 infection

Abstract

Abstract Patients with refractory cardiac sarcoidosis (CS) take a high dose of corticosteroid and immunosuppressive agents. During the pandemic outbreak of severe acute respiratory syndrome coronavirus 2, appropriate treatment of corticosteroids or immunosuppressive agents in CS patients with coronavirus disease 2019 (COVID‐19) is unknown. Here, the woman with refractory CS receiving maintenance therapy with 15 mg of prednisolone daily and 10 mg of methotrexate weekly was emergently admitted to our hospital because of COVID‐19. This case was successfully treated by the intravenous administration of dexamethasone 6 mg/day instead of prednisolone and interruption of methotrexate without resulting in recurrent life‐threatening ventricular lethal arrhythmias or obvious sarcoidosis flare‐ups. She started taking prednisolone and methotrexate at the maintenance dose immediately and at 2 weeks after discharge, respectively. Although the optimal regimen of immunosuppressive agents during COVID‐19 is under intense debate, this report might provide an effective treatment strategy for CS patients with COVID‐19.

Keywords

• Refractory cardiac sarcoidosis
• Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
• Immunocompromised patient
• Immunology